{"title":"可能升高高血压患者血压的出院药物处方。","authors":"Sarasa Miyake, Atsushi Miyawaki, Hiroki Matsui, Yuya Kimura, Hideo Yasunaga","doi":"10.1002/pds.70150","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to determine the frequency of discharge prescriptions of drugs that may raise blood pressure (BP) in hospitalized patients with hypertension and identify factors associated with these prescriptions.</p><p><strong>Methods: </strong>A retrospective cross-sectional analysis was conducted using a nationwide inpatient database in Japan, focusing on adults with hypertension discharged from acute care hospitals between April 2021 and March 2022. The primary outcome was the prescription of drugs that may raise BP at discharge. A multivariable linear probability model was employed to assess the relationship between patient and hospital characteristics and the likelihood of receiving these prescriptions.</p><p><strong>Results: </strong>Among 979 234 patients with hypertension (mean age: 75.3 years, standard deviation: 13.2), 230 792 (23.6%) received at least one drug that may elevate BP at discharge. Non-steroidal anti-inflammatory drugs (NSAIDs) were the most frequently prescribed (46.6%), followed by glucocorticoids (35.3%), atypical antipsychotics (15.1%), antidepressants (7.9%), and Japanese herbal medicines (6.1%). Prescription prevalence was higher among female patients, younger adults, those admitted for medical conditions, non-emergency hospitalizations, patients with disabilities, and those with a Charlson Comorbidity Index of 1. Patients hospitalized for musculoskeletal or skin conditions, transferred to another hospital, or discharged from high-volume hospitals were also more likely to receive these prescriptions.</p><p><strong>Conclusions: </strong>Drugs that may raise BP are commonly prescribed at discharge for patients with hypertension. This highlights the need for targeted interventions to optimize medication management at discharge, aiming to improve BP control and patient outcomes.</p>","PeriodicalId":19782,"journal":{"name":"Pharmacoepidemiology and Drug Safety","volume":"34 5","pages":"e70150"},"PeriodicalIF":2.4000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Hospital Discharge Prescription of Drugs That May Raise Blood Pressure in Patients With Hypertension.\",\"authors\":\"Sarasa Miyake, Atsushi Miyawaki, Hiroki Matsui, Yuya Kimura, Hideo Yasunaga\",\"doi\":\"10.1002/pds.70150\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>This study aimed to determine the frequency of discharge prescriptions of drugs that may raise blood pressure (BP) in hospitalized patients with hypertension and identify factors associated with these prescriptions.</p><p><strong>Methods: </strong>A retrospective cross-sectional analysis was conducted using a nationwide inpatient database in Japan, focusing on adults with hypertension discharged from acute care hospitals between April 2021 and March 2022. The primary outcome was the prescription of drugs that may raise BP at discharge. A multivariable linear probability model was employed to assess the relationship between patient and hospital characteristics and the likelihood of receiving these prescriptions.</p><p><strong>Results: </strong>Among 979 234 patients with hypertension (mean age: 75.3 years, standard deviation: 13.2), 230 792 (23.6%) received at least one drug that may elevate BP at discharge. Non-steroidal anti-inflammatory drugs (NSAIDs) were the most frequently prescribed (46.6%), followed by glucocorticoids (35.3%), atypical antipsychotics (15.1%), antidepressants (7.9%), and Japanese herbal medicines (6.1%). Prescription prevalence was higher among female patients, younger adults, those admitted for medical conditions, non-emergency hospitalizations, patients with disabilities, and those with a Charlson Comorbidity Index of 1. Patients hospitalized for musculoskeletal or skin conditions, transferred to another hospital, or discharged from high-volume hospitals were also more likely to receive these prescriptions.</p><p><strong>Conclusions: </strong>Drugs that may raise BP are commonly prescribed at discharge for patients with hypertension. This highlights the need for targeted interventions to optimize medication management at discharge, aiming to improve BP control and patient outcomes.</p>\",\"PeriodicalId\":19782,\"journal\":{\"name\":\"Pharmacoepidemiology and Drug Safety\",\"volume\":\"34 5\",\"pages\":\"e70150\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2025-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmacoepidemiology and Drug Safety\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/pds.70150\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacoepidemiology and Drug Safety","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/pds.70150","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Hospital Discharge Prescription of Drugs That May Raise Blood Pressure in Patients With Hypertension.
Purpose: This study aimed to determine the frequency of discharge prescriptions of drugs that may raise blood pressure (BP) in hospitalized patients with hypertension and identify factors associated with these prescriptions.
Methods: A retrospective cross-sectional analysis was conducted using a nationwide inpatient database in Japan, focusing on adults with hypertension discharged from acute care hospitals between April 2021 and March 2022. The primary outcome was the prescription of drugs that may raise BP at discharge. A multivariable linear probability model was employed to assess the relationship between patient and hospital characteristics and the likelihood of receiving these prescriptions.
Results: Among 979 234 patients with hypertension (mean age: 75.3 years, standard deviation: 13.2), 230 792 (23.6%) received at least one drug that may elevate BP at discharge. Non-steroidal anti-inflammatory drugs (NSAIDs) were the most frequently prescribed (46.6%), followed by glucocorticoids (35.3%), atypical antipsychotics (15.1%), antidepressants (7.9%), and Japanese herbal medicines (6.1%). Prescription prevalence was higher among female patients, younger adults, those admitted for medical conditions, non-emergency hospitalizations, patients with disabilities, and those with a Charlson Comorbidity Index of 1. Patients hospitalized for musculoskeletal or skin conditions, transferred to another hospital, or discharged from high-volume hospitals were also more likely to receive these prescriptions.
Conclusions: Drugs that may raise BP are commonly prescribed at discharge for patients with hypertension. This highlights the need for targeted interventions to optimize medication management at discharge, aiming to improve BP control and patient outcomes.
期刊介绍:
The aim of Pharmacoepidemiology and Drug Safety is to provide an international forum for the communication and evaluation of data, methods and opinion in the discipline of pharmacoepidemiology. The Journal publishes peer-reviewed reports of original research, invited reviews and a variety of guest editorials and commentaries embracing scientific, medical, statistical, legal and economic aspects of pharmacoepidemiology and post-marketing surveillance of drug safety. Appropriate material in these categories may also be considered for publication as a Brief Report.
Particular areas of interest include:
design, analysis, results, and interpretation of studies looking at the benefit or safety of specific pharmaceuticals, biologics, or medical devices, including studies in pharmacovigilance, postmarketing surveillance, pharmacoeconomics, patient safety, molecular pharmacoepidemiology, or any other study within the broad field of pharmacoepidemiology;
comparative effectiveness research relating to pharmaceuticals, biologics, and medical devices. Comparative effectiveness research is the generation and synthesis of evidence that compares the benefits and harms of alternative methods to prevent, diagnose, treat, and monitor a clinical condition, as these methods are truly used in the real world;
methodologic contributions of relevance to pharmacoepidemiology, whether original contributions, reviews of existing methods, or tutorials for how to apply the methods of pharmacoepidemiology;
assessments of harm versus benefit in drug therapy;
patterns of drug utilization;
relationships between pharmacoepidemiology and the formulation and interpretation of regulatory guidelines;
evaluations of risk management plans and programmes relating to pharmaceuticals, biologics and medical devices.